Literature DB >> 33061187

Long-term experience with valve-sparing root reimplantation surgery in tricuspid aortic valve.

Saadallah Tamer1, Stefano Mastrobuoni1, Mona Momeni2, Gaby Aphram1, Emiliano Navarra1, Alain Poncelet1, Philippe Noirhomme1, Parla Astarci1, Gebrine El Khoury1, Laurent de Kerchove1.   

Abstract

OBJECTIVE: To analyze our long-term experience with valve-sparing reimplantation technique in treating aortic root aneurysm, aortic regurgitation, and aortic dissection in patients with tricuspid aortic valve.
METHODS: Between March 1998 and October 2018, 303 consecutive patients underwent valve-sparing reimplantation in our institution. The mean age of this cohort was 52.9 ± 15 years. Time to event analysis was performed with the Kaplan-Meier method. Risk of death, reoperation, and aortic regurgitation (AR) recurrence were analyzed using the cox-regression method.
RESULTS: In-hospital mortality was 1% (n = 3) of which two were admitted for acute aortic dissection. Median follow-up was 5.81 years ([IQR]: 2.8-10 years). Thirty-nine patients (14.4%) died during follow-up. At 5 and 10 years, overall survival was 92 ± 2%and 75 ± 4.9%, respectively. Seventeen patients required late aortic valve reoperation. Freedom from valve reoperation was 95 ± 2% and 90 ± 3%. Freedom from AR > 2+ and AR > 1+ at 10 years was 91 ± 4% and 71.5 ± 4.6%, respectively. Significant multivariate predictors of death included age, New York Heart Association dyspnea class (NYHA), type A acute dissection (TAAD), and preoperative left ventricular end-diastolic diameter (LVEDD). Significant multivariate predictors of AR recurrence included indication for surgery, previous cardiac surgery, and presence of preoperative AR. Freedom from events like major bleeding, thromboembolic events, and infective endocarditis at 10 years were 97%, 98%, and 96%, respectively.
CONCLUSIONS: Aortic valve-sparing with the reimplantation technique has been performed for over two decades in our institution, and the results in patients with tricuspid aortic valve (TAV) are excellent in terms of survival and freedom from valve-related adverse outcomes including valve reoperation. These results continue supporting the use of valve sparing root replacement using the reimplantation technique (VSRR) in patients with aortic aneurysm, irrespective of whether they have preoperative AR or not. VSRR is safe, durable, and reproducible, but further follow-up, well into the second decade is still necessary. © Indian Association of Cardiovascular-Thoracic Surgeons 2019.

Entities:  

Keywords:  Aortic valve repair; Aortic valve-sparing surgery; Tricuspid aortic valve

Year:  2019        PMID: 33061187      PMCID: PMC7525735          DOI: 10.1007/s12055-019-00842-x

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  41 in total

1.  Opening and closing characteristics of the aortic valve after valve-sparing procedures using a new aortic root conduit.

Authors:  R De Paulis; G M De Matteis; P Nardi; R Scaffa; M M Buratta; L Chiariello
Journal:  Ann Thorac Surg       Date:  2001-08       Impact factor: 4.330

2.  Valve sparing-root replacement with the reimplantation technique to increase the durability of bicuspid aortic valve repair.

Authors:  Laurent de Kerchove; Munir Boodhwani; David Glineur; Michel Vandyck; Jean-Louis Vanoverschelde; Philippe Noirhomme; Gebrine El Khoury
Journal:  J Thorac Cardiovasc Surg       Date:  2011-09-28       Impact factor: 5.209

3.  Guidelines for reporting mortality and morbidity after cardiac valve interventions.

Authors:  Cary W Akins; D Craig Miller; Marko I Turina; Nicholas T Kouchoukos; Eugene H Blackstone; Gary L Grunkemeier; Johanna J M Takkenberg; Tirone E David; Eric G Butchart; David H Adams; David M Shahian; Siegfried Hagl; John E Mayer; Bruce W Lytle
Journal:  J Thorac Cardiovasc Surg       Date:  2008-04       Impact factor: 5.209

4.  Reimplantation of the aortic valve at 20 years.

Authors:  Tirone E David; Carolyn M David; Christopher M Feindel; Cedric Manlhiot
Journal:  J Thorac Cardiovasc Surg       Date:  2016-11-16       Impact factor: 5.209

5.  Midterm results of David V valve-sparing aortic root replacement in acute type A aortic dissection.

Authors:  Bradley G Leshnower; Richard J Myung; LaRonica McPherson; Edward P Chen
Journal:  Ann Thorac Surg       Date:  2015-01-09       Impact factor: 4.330

Review 6.  Aortic valve repair in patients with Marfan syndrome-the "Brussels approach".

Authors:  Stefano Mastrobuoni; Saadallah Tamer; Emiliano Navarra; Laurent de Kerchove; Gebrine El Khoury
Journal:  Ann Cardiothorac Surg       Date:  2017-11

7.  Outcomes of Aortic Valve-Sparing Operations in Marfan Syndrome.

Authors:  Tirone E David; Carolyn M David; Cedric Manlhiot; Jack Colman; Andrew M Crean; Timothy Bradley
Journal:  J Am Coll Cardiol       Date:  2015-09-29       Impact factor: 24.094

8.  Mechanisms of recurrent aortic regurgitation after aortic valve repair: predictive value of intraoperative transesophageal echocardiography.

Authors:  Jean-Benoît le Polain de Waroux; Anne-Catherine Pouleur; Annie Robert; Agnès Pasquet; Bernhard L Gerber; Philippe Noirhomme; Gébrine El Khoury; Jean-Louis J Vanoverschelde
Journal:  JACC Cardiovasc Imaging       Date:  2009-08

9.  Elective David I Procedure Has Excellent Long-Term Results: 20-Year Single-Center Experience.

Authors:  Malakh L Shrestha; Erik Beckmann; Firas Abd Alhadi; Heike Krueger; Fiona Meyer-Bockenkamp; Sebastian Bertele; Nurbol Koigeldiyev; Tim Kaufeld; Felix Fleissner; Wilhelm Korte; Jan Schmitto; Serghei Cebotari; Wolfgang Harringer; Axel Haverich; Andreas Martens
Journal:  Ann Thorac Surg       Date:  2017-12-02       Impact factor: 4.330

10.  David valve-sparing aortic root replacement: equivalent mid-term outcome for different valve types with or without connective tissue disorder.

Authors:  John-Peder Escobar Kvitting; Fabian A Kari; Michael P Fischbein; David H Liang; Anne-Sophie Beraud; Elizabeth H Stephens; R Scott Mitchell; D Craig Miller
Journal:  J Thorac Cardiovasc Surg       Date:  2012-10-17       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.